Invivyd Earnings Call Highlights Trial Progress, Growth

Invivyd ((IVVD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Invivyd’s latest earnings call struck an optimistic tone, emphasizing solid commercial traction for PEMGARDA, rapid progress in its pivotal DECLARATION trial, and a strengthened balance sheet after an April capital raise. Management acknowledged uncertainties around regulatory outcomes, trial event rates, and softer COVID vaccine demand, but argued that strong science, favorable safety signals, and a differentiated positioning in prophylaxis more than offset near-term risks.

PEMGARDA Revenue Growth and Commercial Momentum

PEMGARDA posted a 22% year-over-year revenue increase in the first quarter of 2026, underscoring growing demand despite a broader slowdown in COVID-related products. Management highlighted early indicators that suggest further upside, pointing to investments in direct-to-consumer campaigns and AI-powered outreach intended to boost both disease awareness and brand recognition.

DECLARATION Trial Progress and Recruitment Dynamics

Invivyd reported that its pivotal DECLARATION trial, upsized in April, remains on schedule despite a temporary recruitment pause. Enrollment in the expanded cohort initially exceeded expectations, was briefly throttled to better match anticipated summer case rates, and has now resumed at full speed, with management signaling that completion is expected imminently.

Safety Profile and Reduced Post-Dose Monitoring

A key highlight came from the Independent Data Monitoring Committee, which recommended cutting post-dose monitoring for VYD2311 from two hours to just 30 minutes based on unblinded safety data. Management framed this as evidence of favorable tolerability and a potential operational advantage, since shorter observation windows can lower clinic burden and improve patient throughput.

Neutralization Against Omicron BA.3.2 and Variant Coverage

The company confirmed that its medicines neutralize the Omicron BA.3.2 subvariant, reinforcing confidence in its receptor-binding-domain targeting approach. Executives also cited continued strong neutralization across a range of circulating SARS-CoV-2 variants, arguing that this breadth supports the durability and relevance of their prophylactic antibody strategy as the virus evolves.

Pipeline Expansion and Upcoming LIBERTY Study

Beyond COVID, Invivyd unveiled an expanding discovery pipeline that includes programs in measles, RSV, mumps, rubella, and Lyme disease, signaling ambitions well outside its current franchise. The soon-to-open LIBERTY study will explore how combining vaccines with monoclonal antibodies affects immunology and tolerability, which could shape future combination prevention strategies.

Commercial Readiness and Cash Position

The company is investing ahead of a potential VYD2311 launch, planning to leverage the commercial infrastructure already built around PEMGARDA. Management emphasized that cash levels remain strong following an April at-the-market equity raise, and they expect research and development spending to normalize once the capital-intensive DECLARATION trial begins to wind down.

Efficacy Modeling and Public-Health Perspective

Invivyd spent time defending the public-health value of monoclonal antibodies, citing modeling that suggests vaccines can cause systemic reactogenicity in most recipients while providing limited windows of roughly 50% efficacy. They argued that a low-reactogenicity monoclonal with even 10% to 15% efficacy could still reduce overall symptom burden, and said VYD2311 dosing aims to achieve antibody titers consistent with an expected 70% to 90% protection against symptomatic disease.

Declining COVID Vaccine Utilization and Revenue Trends

Management acknowledged that COVID vaccine utilization and associated revenues are declining, even though they did not quantify the drop. They positioned Invivyd’s prophylactic antibodies as a potential solution for segments of the population that may be underserved by waning vaccine demand or fatigue, suggesting this shift could create both headwinds and opportunities.

Elevated Clinical Spend and Higher Cash Burn

First-quarter results reflected meaningfully higher clinical spending, driven by the upsized DECLARATION program and the push to complete pivotal enrollment. This led to a notable uptick in cash burn compared with the fourth quarter of 2025, though leadership reiterated that this spike should be temporary as major trial activities taper later in the year.

Regulatory and Efficacy Uncertainty

Despite the progress, management was clear that key regulatory outcomes, including potential approval and labeling details, remain uncertain and dependent on the FDA’s interpretation of the data. They also reminded investors that efficacy readouts hinge on real-world attack rates and event accrual, making final results inherently probabilistic rather than guaranteed.

Reduced Surveillance and Variant Detection Challenges

The company noted that genomic sequencing and variant surveillance have declined significantly since 2021, leading to less precise and slower detection of emerging strains. This reduced visibility can complicate planning and response, as wastewater and other monitoring systems may miss early signals of new waves or variant shifts that could affect product performance.

Market Demand Signals and Competitive Landscape

Executives pointed to another firm’s decision to abandon a large vaccine study due to lack of demand as evidence that the market is changing. They pushed back on concerns that vaccine-skeptical communities would reject monoclonal antibodies, arguing that different risk-benefit perceptions and tolerability profiles could support broader acceptance despite some lingering perception risk.

Media Traction and Public Education Headwinds

Invivyd expressed frustration that their efforts to educate the public about immunology and prophylaxis, including opinion pieces and outreach, have garnered limited media attention. Management warned that without stronger communication channels, it may take longer for the broader public to understand and adopt novel prevention options, potentially delaying uptake even if regulators are supportive.

Labeling and Adoption Uncertainty for Monitoring Time

While the reduced post-dose monitoring recommendation is a positive signal, management cautioned that it is uncertain how this change will be reflected in product labeling or implemented in practice. They expect minimal impact on field adoption but conceded that regulators and providers will ultimately determine whether the shorter observation window becomes standard protocol.

Forward-Looking Guidance and Strategic Outlook

Looking ahead, Invivyd guided that DECLARATION recruitment is back at full speed and nearing completion, with the LIBERTY study set to begin enrolling soon. The company expects R&D spending to ease as the pivotal program winds down, continues to see strong PEMGARDA growth, and remains confident that VYD2311’s modeled efficacy, favorable safety profile, and confirmed variant coverage can support a compelling regulatory and commercial case.

Invivyd’s call portrayed a company balancing significant scientific and operational achievements with the realities of shifting COVID demand and regulatory uncertainty. Investors will be watching closely as DECLARATION data mature and regulators weigh in, but for now the trajectory reflects rising commercial momentum, a deepening pipeline, and a management team betting that monoclonal prophylaxis can carve out a durable niche in the post-pandemic landscape.